Tianjin Lisheng Pharmaceutical Co Ltd
SZSE:002393
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tianjin Lisheng Pharmaceutical Co Ltd
Long-Term Debt
Tianjin Lisheng Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tianjin Lisheng Pharmaceutical Co Ltd
SZSE:002393
|
Long-Term Debt
¥4.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥47.6m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥43.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥779.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
84%
|
CAGR 10-Years
-1%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Long-Term Debt
¥4.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
46%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥1.2B
|
CAGR 3-Years
129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tianjin Lisheng Pharmaceutical Co Ltd
Glance View
Tianjin Lisheng Pharmaceutical Co., Ltd. engages in production and sales of chemical medicine tablets, hard capsules, pills, lyophilized powder injections, water injections, and active pharmaceutical ingredient (API). The company is headquartered in Tianjin, Tianjin and currently employs 1,477 full-time employees. The company went IPO on 2010-04-23. The firm's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. The company distributes its products mainly within domestic markets.
See Also
What is Tianjin Lisheng Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
4.5m
CNY
Based on the financial report for Dec 31, 2025, Tianjin Lisheng Pharmaceutical Co Ltd's Long-Term Debt amounts to 4.5m CNY.
What is Tianjin Lisheng Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
-21%
Over the last year, the Long-Term Debt growth was -46%. The average annual Long-Term Debt growth rates for Tianjin Lisheng Pharmaceutical Co Ltd have been -5% over the past three years , and -21% over the past ten years .
